GlobeNewswire by notified

Aino Health AB (publ): Delårsrapport januari-september 2023

Dela

Implementerat 100 000 licenserFörbättrad omsättning, lönsamhet och kassaflöde.


Januari – September 2023

  • Omsättningen uppgick till 17 605 (15 248) TSEK 
  • Resultatet efter finansiella poster -6 812 (-10 522) TSEK
  • Resultatet per aktie uppgick till -0,2 (-0,3) SEK

Juli – September 2023

  • Omsättningen uppgick till 5 633 (4 839) TSEK
  • Resultatet efter finansiella poster -1 215 (-3 127) TSEK
  • Resultatet per aktie uppgick till 0 (-0,1) SEK


Det är med stor tillförsikt som jag vill börja med att vi framgångsrikt har implementerat 100 000 licenser. Det bekräftar vårt förtroendeskapande arbete och kraften i vår plattform. Vi fortsätter att visa på den potential och kraft våra digitala lösningar bär med sig. Jag vill också framhålla den emission vi genomfört under detta kvartal. Denna strategiska åtgärd minskar bolagets skulder och förstärker vår likviditet. Omsättningen för detta kvartal har ökat. Denna ökning reflekterar vårt engagemang, vår hängivenhet och den hårda arbetsinsats som hela teamet bakom Aino har lagt ned. Tillsammans med det förbättrade kassaflödet från den löpande verksamheten, ser vi tydliga tecken på en positiv och hållbar ekonomisk utveckling. Vi lever i en tid när Human Capital Management blir alltmer centralt. Det globala näringslivet förväntar sig inte bara innovativa digitala lösningar, utan ser dem nu som en nödvändighet. Det handlar om transparens i verksamheten, öppen dialog mellan medarbetare och ledning, och en kultur där varje individ känner sig uppskattad. Med vår SaaS-lösning fortsätter vi att leda vägen i att uppfylla dessa förväntningar och behov.

Denna information är sådan som Aino Health AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom Jyrki Eklunds, vd och koncernchef för Aino Health AB, försorg, för offentliggörande den 10 november, 2023 kl. 08.30 CET.

För mer information
Jyrki Eklund, VD
Aino Health
Telefon: +358 40 042 4221

Certified Adviser
Erik Penser Bank
För mer information: https://investors.ainohealth.com/certified-adviser/

Om Aino Health (publ)
Aino Health är den ledande leverantören av Software as a Service-lösningar inom Human Capital Productivity och Employee Sustainability. Företagets kompletta system med SaaS-plattformar och tjänster minskar sjukfrånvaro, sänker relaterade kostnader och förbättrar affärsresultaten genom ökad produktivitet och medarbetarengagemang genom att göra hälsa, välbefinnande och säkerhet till en integrerad del av det dagliga arbetet. För mer information besök www.ainohealth.com

Länk till rapporten
https://investors.ainohealth.com/rapporter-och-dokument/

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Fluence Responds to Misleading Short Seller Report22.2.2024 23:32:54 CET | Press release

ARLINGTON, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence” or “the Company”) (NASDAQ: FLNC), a leading global provider of energy storage products, services, and optimization software for renewables and storage, today issued a statement in response to a report published by a known short-seller. The Company believes that the report is an attempt by a self-interested short-seller to profit at the expense of Fluence’s shareholders by manipulating Fluence’s stock price. We believe that the report contains numerous inaccuracies and distortions. The Company believes it is important to set the record straight regarding three blatant misrepresentations: The short-seller's report references pending litigation between Fluence and Siemens Energy, attempting to characterize it as a "critical and dramatic development." While any dispute with a customer is unfortunate, this is a small, ordinary course commercial dispute arising from a single project. Fluence brought the action

Galapagos announces full year 2023 results and outlook for 202422.2.2024 22:01:00 CET | Press release

Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RTExpanded CAR-T pipeline with start of Phase 1/2 study with BCMA CAR-T product candidate GLPG5301 in rrMMEnrolled first patients in Phase 2 study with TYK2 inhibitor, GLPG3667, in DM and SLEFor strategic reasons, it was decided not to continue development of CD19 CAR-T candidate in rSLEExpanded point-of-care CAR-T network in the U.S. with manufacturing agreements with Landmark Bio and Thermo Fisher Scientific Signed strategic research and license collaboration with Brid

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors22.2.2024 19:02:45 CET | Press release

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors. Diane Souza, Member of the Audit and Compensation Committees, and Thomas Südhof, Chairman of the Scientific Committee, will leave the Board of Directors at the end of their second terms. The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office. The Chairman specified that, in order to prepare as effectively as possible for the end, in 2025, of the term of office as director of F

EVS reports 2023 results22.2.2024 18:30:00 CET | Press release

Publication on February 22, 2024, after market closing Regulated and inside information – Press release annual results EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports 2023 results Liège, Belgium, February 22nd, 2024 EVS further delivers profitable growth in 2023, validating the effectiveness of its PlayForward strategy The robust financial performance of EVS in 2023 underscores the effectiveness of the implemented strategy aimed at fostering sustained and profitable long-term growth. Despite the absence of significant Big Event Rental revenue in an uneven year 2023, EVS achieved record-breaking revenue and demonstrated strong profitability. This success serves as a testament to the efficacy of its PlayForward strategy. Full-year Highlights Order intake outpacing revenue at EUR 192.9 million, including EUR 7.4 million of Big Event Rental (BER).Revenue performance landing north of our guidance at EUR 173.2 million, growing 16.9%

RevoluGROUP Canada Inc. Issues Incentive Share Options22.2.2024 18:23:23 CET | Press release

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") announces that incentive share options to purchase up to 5,200,000 common shares of the Company were granted to consultants and Directors of the Company, with an exercise price of $0.05 per share. The incentive share options have been granted pursuant to the Company's 10% rolling stock option plan and will expire twenty-four months from the grant date. Should all announced options be exercised in the term, the aggregate amount payable to the treasury would be CA $ 260,000. The options are to be granted as shown below: Francisco Moreno Balboa1,500,000Gavin McMillan500,000Bernard Lonis500,000Alfredo Manresa Ruiz500,000Fernando Guillen Hernandez500,000 An additional 1,700,000 options were also granted to consultants in the Company who have provided valuable assistance in the development of products, business development, solution integra

HiddenA line styled icon from Orion Icon Library.Eye